Drugs Made In America Acquisition Corp. DMAA
$10.80
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 196.69% | 247.81% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.69% | 247.81% | -- | -- | -- |
| Operating Income | -196.69% | -247.81% | -- | -- | -- |
| Income Before Tax | 95.46% | 702.30% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 95.46% | 702.30% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.46% | 702.30% | -- | -- | -- |
| EBIT | -196.69% | -247.81% | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 168.11% | 11,105.56% | -- | -- | -- |
| Normalized Basic EPS | 168.13% | 20,533.33% | -- | -- | -- |
| EPS Diluted | 186.73% | 3,244.44% | -- | -- | -- |
| Normalized Diluted EPS | 173.82% | 41,366.67% | -- | -- | -- |
| Average Basic Shares Outstanding | 75.26% | 221.80% | -- | -- | -- |
| Average Diluted Shares Outstanding | 73.61% | 216.38% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |